New Targets in Non-Small Cell Lung Cancer

Soo J Park; Soham More; Ayesha Murtuza; Brian D Woodward; Hatim Husain

doi:10.1016/j.hoc.2016.08.010

New Targets in Non-Small Cell Lung Cancer

Hematol Oncol Clin North Am. 2017 Feb;31(1):113-129. doi: 10.1016/j.hoc.2016.08.010.

Authors

Soo J Park¹, Soham More¹, Ayesha Murtuza¹, Brian D Woodward¹, Hatim Husain²

Affiliations

¹ Division of Hematology and Oncology, Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
² Division of Hematology and Oncology, Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA. Electronic address: hhusain@ucsd.edu.

PMID: 27912827
DOI: 10.1016/j.hoc.2016.08.010

Abstract

With the implementation of genomic technologies into clinical practice, we have examples of the predictive benefit of targeted therapy for oncogene-addicted cancer and identified molecular dependencies in non-small cell lung cancer. The clinical success of tyrosine kinase inhibitors against epidermal growth factor receptor and anaplastic lymphoma kinase activation has shifted treatment emphasize the separation of subsets of lung cancer and genotype-directed therapy. Advances have validated oncogenic driver genes and led to the development of targeted agents. This review highlights treatment options, including clinical trials for ROS1 rearrangement, RET fusions, NTRK1 fusions, MET exon skipping, BRAF mutations, and KRAS mutations.

Keywords: BRAF; Driver mutations; KRAS; MET; NSCLC; NTRK; RET; ROS1.

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Carcinoma, Non-Small-Cell Lung* / metabolism
Drug Delivery Systems / methods*
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Lung Neoplasms* / metabolism
Mutation*
Neoplasm Proteins* / genetics
Neoplasm Proteins* / metabolism

Substances

Antineoplastic Agents
Neoplasm Proteins